Stay updated with breaking news from David Roblin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Edith Hessel, experienced R&D and biopharma executive, named as Chief Scientific Officer Osteoporosis announced as first indication, driven by Relation's proprietary engine for indication
Dr Jennifer Schneider appointed CEO, Dr Helen Bright joins as VP of Research Development, and Professor David Roblin will Chair the Board of Directors Senior appointments support acceleration
DCVC and Magnetic Ventures co-led a $25 million seed financing, with participation from Khosla Ventures, OMERS Ventures, and firstminute Capital, among others Relation Therapeutics, the pioneer of
/PRNewswire/ -- LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, Type 1 diabetes, end...
A team led by Crick group leader Veni Papayannopoulos and UCLH respiratory consultant Joanna Porter, has been awarded The Crick’s annual Sir David Cooksey Prize in Translation for investigating whether the cystic fibrosis drug Dornase alfa could reduce inflammation in the lungs of COVID-19 patients. Click to read more...